Moneeb Ehtesham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Moneeb Ehtesham has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Imad Saeed Khan
Section of Neurosurgery, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
4 shared publicationsReid C. Thompson
Vanderbilt University Medical Center
4 shared publicationsCharles B. Stevenson
A Department of Neurological Surgery, Vanderbilt University Medical Center, 21st Avenue & Garland Street, Nashville, TN 37232, USA
3 shared publications- Keith L. Black
Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, USA
3 shared publications - Reid C. Thompson
Vanderbilt University Medical Center
3 shared publications - John S. Yu
Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2 shared publications
Latest Publications
- 1 January 2015
- Published by Springer Nature
- Vol. 853, 33-47
Isolation and Characterization of Stem Cells from Human Central Nervous System Malignancies
Central Nervous System (CNS) tumors include some of the most invasive and lethal tumors in humans. The poor prognosis in patients with CNS tumors is ascribed to their invasive nature. After the description of a stem cell-like cohort in hematopoietic cancers, tumor stem cells (TSCs) have been isolated from a variety of solid tumors, including brain tumors. Further research has uncovered the crucial role these cells play in the initiation and propagation of brain tumors. More importantly, TSCs have also been shown to be relatively resistant to conventional cytotoxic therapeutics, which may also account for the alarmingly high rate of CNS tumor recurrence. In order to elucidate prospective therapeutic targets it is imperative to study these cells in detail and to accomplish this, we need to be able to reliably isolate and characterize these cells. This chapter will therefore, provide an overview of the methods used to isolate and characterize stem cells from human CNS malignancies.
- 1 January 2015
- Published by Springer Nature
- Vol. 853, 33-47
Isolation and Characterization of Stem Cells from Human Central Nervous System Malignancies
Central Nervous System (CNS) tumors include some of the most invasive and lethal tumors in humans. The poor prognosis in patients with CNS tumors is ascribed to their invasive nature. After the description of a stem cell-like cohort in hematopoietic cancers, tumor stem cells (TSCs) have been isolated from a variety of solid tumors, including brain tumors. Further research has uncovered the crucial role these cells play in the initiation and propagation of brain tumors. More importantly, TSCs have also been shown to be relatively resistant to conventional cytotoxic therapeutics, which may also account for the alarmingly high rate of CNS tumor recurrence. In order to elucidate prospective therapeutic targets it is imperative to study these cells in detail and to accomplish this, we need to be able to reliably isolate and characterize these cells. This chapter will therefore, provide an overview of the methods used to isolate and characterize stem cells from human CNS malignancies.
- 1 January 2015
- Published by Springer Nature
- Vol. 853, 69-83
Laboratory Models for Central Nervous System Tumor Stem Cell Research
Central nervous system (CNS) tumors are complex organ systems comprising of a neoplastic component with associated vasculature, inflammatory cells, and reactive cellular and extracellular components. Research has identified a subset of cells in CNS tumors that portray defining properties of neural stem cells, namely, that of self-renewal and multi-potency. Growing evidence suggests that these tumor stem cells (TSC) play an important role in the maintenance and growth of the tumor. Furthermore, these cells have also been shown to be refractory to conventional therapy and may be crucial for tumor recurrence and metastasis. Current investigations are focusing on isolating these TSC from CNS tumors to investigate their unique biological processes. This understanding will help identify and develop more effective and comprehensive treatment strategies. This chapter provides an overview of some of the most commonly used laboratory models for CNSTSC research.
- 1 January 2015
- Published by Springer Nature
- Vol. 853, 69-83
Laboratory Models for Central Nervous System Tumor Stem Cell Research
Central nervous system (CNS) tumors are complex organ systems comprising of a neoplastic component with associated vasculature, inflammatory cells, and reactive cellular and extracellular components. Research has identified a subset of cells in CNS tumors that portray defining properties of neural stem cells, namely, that of self-renewal and multi-potency. Growing evidence suggests that these tumor stem cells (TSC) play an important role in the maintenance and growth of the tumor. Furthermore, these cells have also been shown to be refractory to conventional therapy and may be crucial for tumor recurrence and metastasis. Current investigations are focusing on isolating these TSC from CNS tumors to investigate their unique biological processes. This understanding will help identify and develop more effective and comprehensive treatment strategies. This chapter provides an overview of some of the most commonly used laboratory models for CNSTSC research.
- 1 January 2015
- Published by Springer Nature
- Vol. 853, 167-187
Emerging Strategies for the Treatment of Tumor Stem Cells in Central Nervous System Malignancies
High-grade central nervous system (CNS) tumors are notorious for high rates of recurrence and poor outcomes. A small cohort of tumor cells, dubbed tumor stem cells (TSC), are now being recognized as an important subset of the tumor that is resistant to chemotherapy and radiotherapy and account for the high recurrence rates. Recent research is developing modalities to target TSCs specifically in a bid to improve the response of the tumor as a whole. The methods being employed to target TSCs include targeting TSC-specific pathways or receptors, TSC-sensitizing agents to chemotherapy and radiotherapy, immunotherapy, TSC-differentiating agents, and viral therapy. This chapter provides an overview of strategies that are expected to help develop new and more effective treatments for CNS tumors.
- 1 January 2015
- Published by Springer Nature
- Vol. 853, 167-187
Emerging Strategies for the Treatment of Tumor Stem Cells in Central Nervous System Malignancies
High-grade central nervous system (CNS) tumors are notorious for high rates of recurrence and poor outcomes. A small cohort of tumor cells, dubbed tumor stem cells (TSC), are now being recognized as an important subset of the tumor that is resistant to chemotherapy and radiotherapy and account for the high recurrence rates. Recent research is developing modalities to target TSCs specifically in a bid to improve the response of the tumor as a whole. The methods being employed to target TSCs include targeting TSC-specific pathways or receptors, TSC-sensitizing agents to chemotherapy and radiotherapy, immunotherapy, TSC-differentiating agents, and viral therapy. This chapter provides an overview of strategies that are expected to help develop new and more effective treatments for CNS tumors.
- 10 October 2014
- Published by Springer Nature
- p. 433-453
Models to Study Glioma Cell Invasion
- 10 September 2014
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 2 (4) , 256-264
Surgical Approaches for Vestibular Schwannoma
- 10 September 2014
- Published by Springer Nature in Current Otorhinolaryngology Reports
- Vol. 2 (4) , 256-264
Surgical Approaches for Vestibular Schwannoma
- Open Access
- 1 January 2014
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 5 (1) , 41
Surgical management of large scalp infantile hemangiomas
Infantile Hemangiomas (IH) are the most common benign tumor of infancy, occurring in over 10% of newborns. While most IHs involute and never require intervention, some scalp IHs may cause severe cosmetic deformity and threaten tissue integrity that requires surgical excision. We present our experience with two infants who presented with large scalp IH. After vascular imaging, the patients underwent surgical resection of the IH and primary wound closure with excellent cosmetic outcome. We detail the surgical management of these cases and review the relevant literature. In some cases the IHs leave behind fibro-fatty residuum causing contour deformity. Surgery is often required for very large lesions causing extensive anatomical and/or functional disruption. The goal of surgical intervention is to restore normal anatomic contour and shape while minimizing the size of the permanent scar.
- 1 January 2014
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 5 (1) , 41
Open AccessSurgical management of large scalp infantile hemangiomas
Infantile Hemangiomas (IH) are the most common benign tumor of infancy, occurring in over 10% of newborns. While most IHs involute and never require intervention, some scalp IHs may cause severe cosmetic deformity and threaten tissue integrity that requires surgical excision. We present our experience with two infants who presented with large scalp IH. After vascular imaging, the patients underwent surgical resection of the IH and primary wound closure with excellent cosmetic outcome. We detail the surgical management of these cases and review the relevant literature. In some cases the IHs leave behind fibro-fatty residuum causing contour deformity. Surgery is often required for very large lesions causing extensive anatomical and/or functional disruption. The goal of surgical intervention is to restore normal anatomic contour and shape while minimizing the size of the permanent scar.
- 14 March 2013
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 113 (2) , 153-162
The role of the CXCR4 cell surface chemokine receptor in glioma biology
CXCR4, a cell surface chemokine receptor, mediates cellular dissemination, invasion, and proliferation in a wide range of cancers including gliomas. It is over-expressed in glioma progenitor cells, and its protein ligand, CXCL12, has been shown to mediate a specific proliferative response in these cells thereby implicating a role for CXCR4 in glioma initiation and renewal. Given the failure of currently employed therapies to meaningfully impact prognosis in patients with high-grade gliomas, the CXCR4–CXCL12 axis represents a novel biologically relevant mechanism that could be specifically targeted for therapy. From this perspective, this review summarizes the biological effects of CXCR4 activity and its implications for glioma pathogenesis. Ultimately, the development of effective treatment approaches for malignant glioma must be based on a rational mechanistic understanding of tumor cell biology. As such, this article presents such a framework with regard to the CXCR4 pathway in glioma thereby supporting the further investigation of CXCR4 as a therapeutic target in patients with this disease.
- 14 March 2013
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 113 (2) , 153-162
The role of the CXCR4 cell surface chemokine receptor in glioma biology
CXCR4, a cell surface chemokine receptor, mediates cellular dissemination, invasion, and proliferation in a wide range of cancers including gliomas. It is over-expressed in glioma progenitor cells, and its protein ligand, CXCL12, has been shown to mediate a specific proliferative response in these cells thereby implicating a role for CXCR4 in glioma initiation and renewal. Given the failure of currently employed therapies to meaningfully impact prognosis in patients with high-grade gliomas, the CXCR4–CXCL12 axis represents a novel biologically relevant mechanism that could be specifically targeted for therapy. From this perspective, this review summarizes the biological effects of CXCR4 activity and its implications for glioma pathogenesis. Ultimately, the development of effective treatment approaches for malignant glioma must be based on a rational mechanistic understanding of tumor cell biology. As such, this article presents such a framework with regard to the CXCR4 pathway in glioma thereby supporting the further investigation of CXCR4 as a therapeutic target in patients with this disease.
- 1 February 2009
- Published by Elsevier in Cancer Letters
- Vol. 274 (2) , 305-312
CXCR4 mediates the proliferation of glioblastoma progenitor cells
- 1 February 2009
- Published by Elsevier in Cancer Letters
- Vol. 274 (2) , 305-312
CXCR4 mediates the proliferation of glioblastoma progenitor cells
- 1 September 2008
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 63 (3) , 560-570
CXCR4 EXPRESSION IS ELEVATED IN GLIOBLASTOMA MULTIFORME AND CORRELATES WITH AN INCREASE IN INTENSITY AND EXTENT OF PERITUMORAL T2-WEIGHTED MAGNETIC RESONANCE IMAGING SIGNAL ABNORMALITIES
OBJECTIVE. With the objective of investigating the utility of CXCR4, a chemokine receptor known to mediate glioma cell invasiveness, as a molecular mark
- 1 September 2008
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 63 (3) , 560-570
CXCR4 EXPRESSION IS ELEVATED IN GLIOBLASTOMA MULTIFORME AND CORRELATES WITH AN INCREASE IN INTENSITY AND EXTENT OF PERITUMORAL T2-WEIGHTED MAGNETIC RESONANCE IMAGING SIGNAL ABNORMALITIES
OBJECTIVE. With the objective of investigating the utility of CXCR4, a chemokine receptor known to mediate glioma cell invasiveness, as a molecular mark
- 9 January 2006
- Published by Springer Nature in Oncogene
- Vol. 25 (19) , 2801-2806
CXCR4 expression mediates glioma cell invasiveness
Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25- to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.
- 9 January 2006
- Published by Springer Nature in Oncogene
- Vol. 25 (19) , 2801-2806
CXCR4 expression mediates glioma cell invasiveness
Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25- to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.